Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Allogeneic gene therapy with BMP-2-transduced mesenchymal stem cells combined with immunosuppression enhances bone healing.

Ball JR., Gallo MC., Wier J., Hernandez F., Shelby T., Elias A.

Animal Study on Immune Modulation, published in Mol Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Ther (2025)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41088754
DOI
10.1016/j.ymthe.2025.10.028

Abstract (original English)

Critical-sized bone defects remain a significant clinical challenge with limited treatment options. This study investigated whether allogeneic adipose-derived stem cells (ADSCs) transduced with a lentiviral vector to express BMP-2 could effectively heal femoral defects in immune competent rats with or without temporary FK506 (i.e., tacrolimus) immunosuppression. Forty-three Lewis rats with 6 mm mid-diaphyseal femoral defects received either BMP-2-transduced or non-transduced allogeneic ADSCs from Sprague-Dawley donors, with or without FK506. At 12 weeks, immunosuppressed rats receiving BMP-2-transduced ADSCs achieved healed bone with significantly higher torsional stiffness, peak torque, and energy to failure compared with those not receiving immunosuppression. Similarly, radiographic healing scores, histology, and micro-CT analysis revealed greater new bone formation in immunosuppressed animals. Non-transduced ADSCs produced minimal bone healing regardless of immunosuppression. FK506 did not enhance in vitro BMP-2 production or osteogenic differentiation, suggesting its primary benefit at the tested dose was immunomodulatory rather than enhancing osteoinductive activity. These findings establish that temporary immunosuppression dramatically enhances the efficacy of allogeneic cell-based gene therapy for bone regeneration without significant complications, potentially enabling

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsBone Morphogenetic Protein 2RatsGenetic TherapyMesenchymal Stem CellsOsteogenesisTransduction, GeneticBone RegenerationGenetic VectorsMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research